AJP - Regu Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 268: R395-R402, 1995;
0363-6119/95 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilkins, F. C.
Right arrow Articles by Granger, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilkins, F. C., Jr
Right arrow Articles by Granger, J. P.

AJP - Regulatory, Integrative and Comparative Physiology, Vol 268, Issue 2 395-R402, Copyright © 1995 by American Physiological Society


ARTICLES

Chronic endothelin-induced pressor and renal actions in conscious dogs do not require altered ANG II formation

F. C. Wilkins Jr, S. Kassab, T. Kato, H. L. Mizelle, T. J. Opgenorth and J. P. Granger
Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson 39216.

Plasma endothelin levels are elevated approximately two- to threefold in a number of chronic pathophysiological conditions associated with hypertension. Results from recent studies indicate an important interaction between endothelin and the renin-angiotensin system (RAS). The role of the RAS in mediating the increases in arterial pressure produced by long-term pathophysiological elevations in circulating levels of endothelin is unknown. Therefore, the purpose of this study was to chronically increase circulating levels of endothelin within the pathophysiological range and determine the long-term cardiovascular and renal actions of endothelin in control dogs (n = 6) and in dogs pretreated with a converting-enzyme inhibitor (CEI) (n = 6) or CEI + angiotensin II (ANG II) replacement (n = 6). Infusion of endothelin-1 for 8 days at a rate of 2.5 ng.kg-1.min-1 increased plasma endothelin from 7.1 +/- 0.9 to 19.8 +/- 3.3 pg/ml. In control dogs, endothelin increased mean arterial pressure (MAP) by 19% (90 +/- 2 to 107 +/- 3 mmHg) while decreasing renal blood flow (RBF) by 30% and glomerular filtration rate (GFR) by 15-20%. Long-term elevation of circulating endothelin produced similar elevations in MAP in dogs pretreated with CEI (+16%) or CEI + ANG II (+17%). Similar decreases in RBF and GFR also occurred in response to endothelin in all three groups. These results indicate that although long-term increases in circulating endothelin within the pathophysiological range produce significant increases in arterial pressure, this effect does not appear to be mediated by the RAS.


This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Wang, A. F. Chen, and D. H. Wang
ETA receptor blockade prevents renal dysfunction in salt-sensitive hypertension induced by sensory denervation
Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2005 - H2011.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. A. Elmarakby, P. Morsing, and D. M. Pollock
Regulation of Cardiovascular Signaling by Kinins and Products of Similar Converting-Enzyme Systems: Enalapril attenuates endothelin-1-induced hypertension via increased kinin survival
Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H1899 - H1903.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. Henrion, M. Iglarz, and B. I. Levy
Chronic Endothelin-1 Improves Nitric Oxide–Dependent Flow-Induced Dilation in Resistance Arteries From Normotensive and Hypertensive Rats
Arterioscler. Thromb. Vasc. Biol., September 1, 1999; 19(9): 2148 - 2153.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
G. S. Potter, R. J. Johnson, and G. D. Fink
Role of Endothelin in Hypertension of Experimental Chronic Renal Failure
Hypertension, December 1, 1997; 30(6): 1578 - 1584.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online